Radiance HTN Study

Statement from Deborah Heart and Lung Center
May 23, 2018

“As the Principal Investigator on this research trial at Deborah Heart and Lung Center, we have had the distinct privilege of being the highest volume research site in the world. This has given us a great deal of first-hand insight into the study and the possibility of revolutionizing how we treat hypertension. High blood pressure is the number one cause for cardiovascular mortality and morbidity. One in two American suffers from hypertension and more than a third of them have uncontrolled blood pressure. For years there have been no new breakthroughs on the market to address this spiraling problem. Renal denervation offers the first tangible evidence for a new approach. I am not surprised that the clinical trial results are favorable and show so much promise for on-going treatment. This confirms the results at our facility. I am now looking forward to the next phase of the trial and the anticipation of an approved alternate treatment for hypertension in the next few years. I expect when that happens Deborah –with this new tool in our arsenal – will become a major Hypertension Center of Excellence.”

 

Kintur Sanghvi, MD
Associate Medical Director of Interventional Cardiology
Deborah Heart and Lung Center
Browns Mills, NJ

Radiance HTN Study

https://demanddeborah.org/bloodpressure/